Skip to main content

Advertisement

Table 3 Multivariable models showing association between prestroke statins use, NIHSS and Prognosis

From: Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke

  OR (95% CI) P*
Model 1 (baseline Ox-LDL)
 Prestroke Statins use
  Mortality 0.38(0.16–0.91) 0.031
  Major disability (mRs3–5) 0.38 (0.15–0.99) 0.047
  Major disability (mRs3–5) + death 0.31(0.17–0.74) 0.009
 NIHSS score
  Mortality 1.18(1.10–1.26) < 0.001
  Major disability (mRs3–5) 1.17(1.06–1.30) 0.003
  Major disability (mRs3–5) + death 1.20(1.10–1.29) < 0.001
Model 2(3-month Ox-LDL levels)
 Prestroke Statins use
  Mortality 0.36(1.15–0.87) 0.023
  Major disability (mRs3–5) 0.38(0.15–0.95) 0.038
  Major disability (mRs3–5) + death 0.27(0.11–0.64) 0.003
 NIHSS score
  Mortality 1.18(1.11–1.27) < 0.001
  Major disability (mRs3–5) 1.17(1.06–1.30) 0.003
  Major disability (mRs3–5) + death 1.19(0.10–1.29) < 0.001
  1. Bold indicates P-values less than 0.05
  2. *Multivariable adjusted for age, baseline NIHSS score, mean AF duration, CHA2DS2-VASc score, sex, BMI, hypertension, current smoking, current alcohol consumption, diabetes, hyperlipidemia, AF type, family history of stroke, prestroke statins use, baseline Ox-LDL levels (3-month Ox-LDL levels) and use of antihypertensive, warfarin, direct oral anticoagulants, antiplatelets